Malignant Solid Tumor Clinical Trial
Official title:
A Pilot Trial of Ifetroban, A Thromboxane A2 Receptor Antagonist, in Patients With Malignant Solid Tumors at High Risk of Metastatic Recurrence
This pilot trial studies the side effects of ifetroban in treating patients with malignant solid tumors that are at high risk of coming back after treatment and spreading throughout the body. Platelets are a type of blood cells that help with clotting. Cancer cells stick to platelets and ride on them to get to different parts of the body. Drugs, such as ifetroban, may help these platelets become less "sticky," and reduce the chance of cancer cells spreading to other places in the body.
PRIMARY OBJECTIVES: I. To assess the safety and feasibility of ifetroban sodium (ifetroban) administration in patients with malignant solid tumors at high risk of metastatic recurrence, after completion of all planned (neo)adjuvant locoregional and systemic therapies. SECONDARY OBJECTIVES: I. To assess rate of metastatic recurrence after completion of ifetroban in patients with malignant solid tumors. EXPLORATORY OBJECTIVES: I. To quantify pharmacodynamic markers of ifetroban effects. OUTLINE: Patients are randomized to 1 of 2 groups. GROUP 1 (IFETROBAN): Patients receive ifetroban sodium orally (PO) once daily (QD). Courses repeat every 28 days for 12 months in the absence of disease progression or unacceptable toxicity. GROUP 2 (PLACEBO): Patients receive a placebo PO QD. Courses repeat every 28 days for 12 months in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up at 30 days, then up to 12 months. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT01846429 -
Oral Bicarbonate as Adjuvant for Pain Reduction in Patients With Tumor Related Pain
|
Phase 1 | |
| Completed |
NCT01359982 -
Safety and Pharmacokinetic Study of RRx-001 in Cancer Subjects
|
Phase 1 | |
| Completed |
NCT01648764 -
A Study of LY2334737 in Participants With Cancer That is Advanced and/or Has Spread
|
Phase 1 | |
| Completed |
NCT00725634 -
A Phase 1 Dose-Escalation Study in Advanced Solid Tumors, Lymphomas or Multiple Myeloma
|
Phase 1 | |
| Recruiting |
NCT04083599 -
GEN1042 Safety Trial and Anti-tumor Activity in Subjects With Malignant Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05141474 -
Assessment of the Safety and Tolerability of ex Vivo Next-generation Neoantigen-selected Tumor-infiltrating Lymphocyte (TIL) Therapy in Advanced Epithelial Tumors and Immune Checkpoint Blockade (ICB) Resistant Solid Tumors
|
Early Phase 1 | |
| Active, not recruiting |
NCT02999750 -
EXtendedAnalysis for Cancer Treatment
|
N/A | |
| Completed |
NCT01457118 -
An Extension Study of NKTR-102 in Cancer Patients Previously Enrolled in NKTR-102 Studies
|
Phase 2 | |
| Active, not recruiting |
NCT05539157 -
Study to Evaluate JCXH-211 as Monotherapy in Patients With Malignant Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT04571892 -
A Clinical Study to Observe the Safety and Efficacy of ScTIL210 in the Treatment of Malignant Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05468359 -
Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04168528 -
Phase I/IIa Study of 68GaNOTA-Anti-MMR-VHH2 for PET/CT
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04145622 -
Study of Ifinatamab Deruxtecan (I-DXd) in Participants With Advanced Solid Malignant Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06057038 -
A Safety Trial of GEN1042 in Japanese Subjects With Malignant Solid Tumors
|
Phase 1 | |
| Completed |
NCT02844400 -
Cancer Patients' Performance Status Assessed Using Cardiopulmonary Exercise Testing and Wearable Data Generation
|
||
| Completed |
NCT00452413 -
A Study of Enzastaurin and Erlotinib in Participants With Solid Tumors and Lung Cancer
|
Phase 1/Phase 2 | |
| Completed |
NCT03553108 -
A Study Using Olaparib Tablets for Subjects With Advanced Solid Tumours.
|
Phase 1 | |
| Recruiting |
NCT04076137 -
Targeted T-cell Therapy in Solid Tumors
|
Early Phase 1 | |
| Terminated |
NCT03192345 -
A First-in-human Study of the Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of SAR439459 Monotherapy and Combination of SAR439459 and Cemiplimab in Patients With Advanced Solid Tumors
|
Phase 1 | |
| Completed |
NCT02754141 -
An Investigational Immuno-therapy Study of Experimental Medication BMS-986179 Given Alone and in Combination With Nivolumab
|
Phase 1/Phase 2 |